NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of May 21, 2026, NEO trades at $8.85 with a market cap of $1.09B and a P/E ratio of 0.00. NEO moved +6.08% today. Year to date, NEO is -26.32%; over the trailing twelve months it is +11.39%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.94. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded NEO stock?
Recent politician trading activity in NEO includes disclosures from Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
NEO Key Metrics
Key financial metrics for NEO
Metric
Value
Price
$8.85
Market Cap
$1.09B
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
0.00%
52-Week High
$19.12
52-Week Low
$4.72
Volume
4.23K
Avg Volume
0
Revenue (TTM)
$727.33M
Net Income
$-108.03M
Gross Margin
43.21%
Congressional Trades in NEO
Gilbert Cisneros purchase NEO on May 7, 2025 (amount: $15.00K).
Recent politician trading activity in NEO includes disclosures from Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in NEO?
Yes. Rallies tracks politician and congressional stock disclosures for NEO, including reported purchases, sales, dates, owners, and trade amounts when available.
Is NEO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.
